Who Cares About Dr. Adam Cifu’s Plan to Fix EBM in Theory, When in Reality, He Elevated the MAHA Doctors Wrecking it Today?

Evidence-based medicine, or EBM, is supposed to be the adult in the room. It is the person at the party who says, “That sounds exciting, but do we have actual data?” It is not glamorous. It does not wear a cape. It mostly carries a clipboard and ruins everyone’s favorite anecdote. And that is exactly why it matters.

Dr. Adam Cifu has spent years building a reputation as one of EBM’s more credible custodians. He is not a fringe crank with a ring light and a podcast microphone. He is a University of Chicago professor, a practicing internist, and the co-author of Ending Medical Reversal, a book built around a stubbornly sensible point: medicine goes off the rails when clinicians adopt practices before the evidence is ready. Fair enough. More than fair, actually. That is one of the central problems of modern medicine.

So when Cifu talks about fixing EBM, people listen. Or at least they should. His diagnosis of the problem is often sharp. He has argued that evidence-based medicine has been bent by industry incentives, distorted trial design, weak observational research, publication inflation, and a professional culture that rewards volume over truth. In one recent formulation, he called for unbiased research, trials designed by practicing physicians around real clinical questions, and fewer but better studies. On paper, that sounds like common sense wearing a white coat.

But here is the problem: theory is cheap. Especially in medicine. Especially online. Especially when your platform has already helped legitimize the very doctors and political actors now turning “gold-standard science” into a bumper sticker while hacking away at the institutions that make science usable in the first place.

Adam Cifu’s diagnosis of EBM’s problems is not the issue

To be blunt, Cifu is right about a lot of what is broken. Evidence-based medicine has real structural weaknesses. Plenty of trials are technically polished but clinically hollow. Surrogate endpoints are often treated like they are actual patient outcomes. Weak observational studies get laundered into headlines. Industry money can shape what gets studied, how it gets studied, and how it gets spun. Academic prestige often rewards productivity, not reliability. By the time a flashy claim gets shredded by better evidence, the TED Talk has already happened and the book tour has already left the station.

None of this is imaginary. If anything, it is familiar enough to qualify as medicine’s background music. So yes, by all means, talk about publication bias, methodological slop, and the professional incentives that create medical reversals. That conversation is necessary.

What is not acceptable is pretending that these concerns become less urgent when the people bending evidence are your ideological allies, your editorial colleagues, your favored contrarians, or the folks who happen to share your enemies.

The credibility gap opens when theory meets political friendship

This is where the story gets awkward. Cifu is one of the editors of Sensible Medicine, a platform that presents itself as a home for “common sense and original thinking” in medicine. Fine. Debate is healthy. Heterodoxy is not a crime. But editorial judgment is still judgment. A platform is not a weather system. Things do not simply “appear” on it like mushrooms after rain.

And what appeared there mattered.

Sensible Medicine hosted and promoted content such as Why Doctors Should Learn to Stop Worrying and Love MAHA. It also published a piece arguing that Robert F. Kennedy Jr.’s nomination as HHS secretary could be “a new beginning” and predicted he would be a net positive for public health. That was not a small rhetorical gamble. That was not an innocent thought experiment. That was a decision to lend medical legitimacy, editorial cover, and intellectual polish to an agenda that was already soaked in distrust of public health institutions and marinated in performative anti-establishmentism.

Once you do that, you do not get to hide behind abstraction later. You do not get to say, “Well, I simply care about better evidence.” Not when your platform helped elevate people who now invoke “evidence” the way a stage magician invokes smoke.

This is not guilt by association. It is responsibility by amplification.

There is a lazy way to make this argument and a serious way. The lazy way is to say Cifu agrees with everything every MAHA-aligned figure has done. That would be unfair. The serious way is to say that he helped build a prestige ecosystem in which contrarian doctors were presented not merely as critics of bad science, but as the adults who would restore rigor once they got power. That claim has aged like unrefrigerated sushi.

The problem is not that Cifu knows these people. The problem is that he treated them as trustworthy reformers of evidence-based medicine at precisely the moment they were poised to test that claim in the real world.

And then the real world arrived, carrying a folding chair

The MAHA project talks a lot about transparency, root causes, and gold-standard research. The official language sounds polished enough to frame in a policy school hallway. The White House order establishing the MAHA Commission promised transparency, open-source data, and rigorous research into the drivers of childhood chronic disease. The rhetoric was classic reform language: clear out conflicts, ask hard questions, put patients first, stop the capture.

Sounds terrific. Also sounds familiar. Every era’s favorite wrecking crew says it is here to save the cathedral.

Then came the flagship MAHA report on children’s health, and the whole “gold-standard science” branding exercise ran face-first into a brick wall of embarrassing reality. The report was criticized for citing studies that did not exist, misdescribing other studies, and relying on references so messy that even sympathetic observers had to start doing the thing where they stare into the middle distance and sigh. Nothing says “we are restoring trust in science” quite like having to explain why your science report appears to have footnotes assembled by a sleepy intern and a possessed autocomplete box.

That should have been a five-alarm fire for anyone serious about EBM. Not a shrug. Not a throat-clearing exercise about how the broader concerns still matter. Not another sermon about nuance. When a movement brands itself as a revolt against corrupted expertise and then produces error-riddled evidence to justify policy, that is not a side issue. That is the issue.

Meanwhile, the institutions EBM depends on were getting kicked in the shins

Evidence-based medicine is not just a philosophy. It is an ecosystem. It depends on functioning research institutions, independent review panels, trustworthy advisory processes, stable grant systems, and regulators who do not confuse ideological swagger with methodological rigor. Break those things, and EBM becomes a PowerPoint aesthetic.

That is why the MAHA-era record matters so much.

Under Robert F. Kennedy Jr., the CDC’s vaccine advisory committee was purged and replaced, triggering alarm from physicians, public health groups, and even the fired members themselves, who warned that the moves weakened the national immunization program and put families at risk. As of March 2026, a federal judge had temporarily blocked major parts of Kennedy’s vaccine changes. Whatever one thinks of reform in theory, replacing structured scientific procedure with politically charged disruption is not a serious recipe for trust. It is governance by table flip.

At the NIH, Jay Bhattacharya took office with a reputation as a lockdown critic and a public face of pandemic dissent. Officially, the agency was also aligned with the goals of the MAHA Commission. In practice, the period has been marked by deep turmoil over research funding, terminated grants, and unusually public criticism from NIH scientists who said the cuts were harming health research and politicizing science. You cannot claim to be rescuing evidence while hollowing out the institutions that produce it.

At the FDA, Marty Makary and Vinay Prasad became symbols of the medical-contrarian ascendancy. Prasad, whom Cifu has praised as a figure whose appointment made sense on EBM grounds, took over the FDA center responsible for biologics and vaccines. He later became a lightning rod for disputes over rare-disease products, vaccine oversight, and regulatory consistency. Then came the extra wrinkle: Makary and Prasad publicly argued that the old expectation of two pivotal studies for drug approval should give way more often to one. Maybe there are cases where that is reasonable. But it is a little rich to watch self-described guardians of rigor move from “medicine adopts too much with too little proof” to “one study should often do the trick” once they control the levers.

This is the broader pattern: hypercritical language about evidence when criticizing the old order, followed by selective flexibility when allies inherit power. That is not a reform movement. That is a costume change.

Why this matters for Cifu specifically

Because Cifu’s brand is not raw partisanship. His brand is credibility. He is supposed to be the sober one. The clinician who knows how easily medicine confuses plausibility with proof. The teacher who explains why strong feelings are not data. The author who warns that medicine hurts people when it acts before the evidence is ready.

That background makes his blind spot more damaging, not less.

If a random influencer with “truth seeker” in their bio helps launder MAHA nonsense into respectable language, that is annoying. If a physician with Cifu’s pedigree helps create a respectable home for the same process, that is consequential. He knows what bad evidence looks like. He knows what motivated reasoning looks like. He literally wrote a book about medicine getting carried away before the data are mature. So when he lends credibility to a coalition now associated with advisory-panel upheaval, evidence sloppiness, institutional destabilization, and selective standards, the contradiction is impossible to ignore.

In other words, Cifu’s problem is not that he wants to fix EBM. It is that he treated political alignment like a sterilizing agent.

Once the doctors he elevated were inside the machinery of HHS, NIH, and FDA, the question stopped being whether they sounded clever on Substack. The question became whether they would protect the hard, boring processes that make evidence trustworthy. Too often, the answer has been some version of: only when convenient.

What actually fixing evidence-based medicine would require

Real EBM reform would start with a willingness to apply the same standards to your friends that you apply to your enemies. It would mean opposing industry distortion and ideological distortion. It would mean defending randomized evidence when it is inconvenient, not just when it is rhetorically useful. It would mean respecting advisory structures even when you dislike their consensus. It would mean admitting that institutions can be flawed without treating demolition as a synonym for improvement.

It would also mean resisting the seductive idea that every justified criticism of mainstream medicine should automatically become an alliance with anti-establishment politics. Plenty of institutional critics are right about real problems and still terrible at building anything better. Knowing where the cracks are is not the same as knowing how to keep the building standing.

Most of all, actual EBM reform would require moral consistency. If you call out bad trials, call out bad citations. If you denounce publication bias, denounce politicized advisory purges. If you worry about weak evidence changing clinical practice, worry about weak evidence changing national health policy. Anything less is not evidence-based medicine. It is evidence-themed branding.

The real question is not whether Cifu’s ideas are good

Many of them are. The real question is whether anyone should trust a reform project that remains eloquent about rigor in seminars and strangely relaxed about rigor when its own crowd is in charge.

That is why the title’s irritation is justified. Who cares about Adam Cifu’s neat theoretical plan to rescue EBM if, in practice, he helped elevate doctors and institutions now undermining the norms EBM actually needs? Who cares about another polished lecture on trial design when the broader political and professional ecosystem around you is replacing method with mood, process with grievance, and transparency with a talking point?

The crisis here is not that Cifu misdiagnosed EBM’s weaknesses. It is that he seemed to believe those weaknesses would somehow disappear once the contrarians took over. They did not. In several places, they got worse, louder, and more openly ideological.

Evidence-based medicine does need fixing. Desperately. But it will not be repaired by people who treat rigor as a weapon against opponents and a courtesy exemption for allies. And it certainly will not be repaired by editors who platform that contradiction and then act surprised when it starts governing.

How this lands in real life: the experience behind the argument

This debate can sound abstract until you picture where it actually lands. It lands in exam rooms, residency conferences, research offices, parent group chats, and the exhausted little spaces where people are just trying to figure out who still deserves their trust. That is why the disconnect between EBM-in-theory and MAHA-in-practice feels so corrosive.

Think about the experience of an ordinary primary care doctor trying to explain vaccine recommendations to a worried parent. The parent is not reading policy memos. They are hearing that official committees were purged, that new appointees are changing guidance, that judges are stepping in, and that every side says they are the real defenders of science. The doctor is left doing translation work for a system that looks less like a steady institution and more like a family group text after someone brings up politics at Thanksgiving. Confidence does not collapse because the science suddenly disappeared. Confidence collapses because the process starts looking rigged, erratic, or openly tribal.

Now think about the medical trainee. The resident or fellow who was taught to be suspicious of weak subgroup analyses, cautious about surrogate outcomes, and honest about uncertainty. Then they watch public figures who built their reputations on that same skepticism become much more flexible when power is involved. One week the lesson is “do not overinterpret thin evidence.” The next week the lesson seems to be “unless our side is making the call.” That kind of inconsistency does not just create cynicism. It trains the next generation to think that evidence rules are optional social tools rather than durable professional norms.

Then there is the researcher experience. Imagine spending years writing grants, collecting data, recruiting patients, revising manuscripts, and surviving peer review, only to watch the people speaking most loudly about “gold-standard science” preside over instability in funding, public attacks on expertise, and sloppy citation disasters in government-facing documents. Researchers are not shocked by criticism. Criticism is part of the job. What wears people down is hypocrisy: the performance of rigor without the discipline of rigor.

And for patients, the experience is even simpler. They do not care which intellectual faction wins the argument on social media. They care whether the recommendation in front of them is grounded, stable, and honestly explained. They care whether their child’s vaccine schedule, their cancer treatment, or their chronic disease management plan is shaped by careful evidence or by ideological turbulence dressed up as reform. Patients can tolerate uncertainty. What they cannot tolerate for long is the feeling that uncertainty is being selectively manipulated.

That is why this whole episode matters beyond one doctor or one newsletter. It is about what betrayal feels like when it arrives wearing the language of reform. People were told that the old system was corrupted by prestige, incentives, and weak evidence, and that a new class of skeptical doctors would clean house. Instead, too much of the result has been a strange mix of swagger, selective standards, institutional damage, and credibility leaks. That experience stays with people. It makes clinicians more guarded, researchers more demoralized, and patients more suspicious. And once that trust is burned, there is no randomized controlled trial that can regrow it overnight.

Conclusion

Dr. Adam Cifu is correct that evidence-based medicine has serious problems. He is correct that clinical research is too often biased, bloated, and built around the wrong incentives. He is correct that medicine needs more humility and better proof before practice. But that is exactly why his real-world choices matter so much.

You do not get full credit for diagnosing bad evidence if you help elevate the people turning bad evidence, broken process, and ideological selectivity into health policy. You do not get to play EBM’s reformer in theory while serving as a kind of intellectual concierge for the crowd wrecking it in practice.

If Cifu wants to fix EBM, great. Start here: apply the standard evenly. To journals, to regulators, to government reports, to vaccine policy, to your own editorial ecosystem, and especially to your friends. Otherwise, all that talk about rigor is just another elegant way to lower the guardrails.